# SUPPORTING INFORMATION

# Interception of Amide Ylides with Sulfonamides: Synthesis of (*E*)-*N*-Sulfonyl Amidines Catalyzed by Zn(OTf)<sub>2</sub>

Jijun Chen, Wenhao Long, Shangwen Fang, Yonggang Yang,\* and Xiaobing Wan\*

Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry,

Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, P.

R. China

Email: wanxb@suda.edu.cn

**List of Contents** 

General Information	
General Procedures for Reactions	S2
Optimization of the Reaction Conditions	S4
Mechanistic Probes	
Compound Characterizations	S14
References	S44
Spectroscopic Data for Products	
XRD Data of the Compound 4a and 8d	S123

# **General Information**

All manipulations were carried out under air atmosphere. Column chromatography was generally performed on silica gel (300-400 mesh) and reactions were monitored by thin layer chromatography (TLC) using UV light to visualize the course of the reactions. The <sup>1</sup>H NMR (400MHz) and <sup>13</sup>C NMR (100MHz) data were recorded using CDCl<sub>3</sub> as solvent at room temperature unless specified otherwise. <sup>19</sup>F NMR (376 MHz) data was recorded using CDCl<sub>3</sub> as solvent at room temperature unless specified otherwise. <sup>19</sup>F NMR (376 MHz) data was recorded using CDCl<sub>3</sub> as solvent at room temperature. The chemical shifts ( $\delta$ ) are reported in ppm and coupling constants (*J*) in Hz. <sup>1</sup>H NMR spectra was recorded with tetramethylsilane ( $\delta$ = 0.00 ppm) as internal reference; <sup>13</sup>C NMR spectra was recorded with CDCl<sub>3</sub> ( $\delta$  = 77.00 ppm) as internal reference. IR, MS, HRMS, and GC-MS were performed by the State-authorized Analytical Center in Soochow University.

# **General procedures for reactions**

### (a) The procedure for the synthesis of *N*-arylpyrrolidone<sup>1</sup>

A flame-dried resealable Schlenk tube was charged with Pd(OAc)<sub>2</sub> (8.8 mg, 0.04 mmol, 1 mol%), Xantphos (34.8 mg, 0.06 mmol, 1.5 mol%), the solid reactant(s) (4.0 mmol of the aryl halide/triflate and 4.8 mmol of the amide), and Cs<sub>2</sub>CO<sub>3</sub> (1824 mg, 5.6 mmol). The Schlenk tube was capped with a rubber septum, evacuated and backfilled with argon; this evacuation/backfill sequence was repeated one additional time. The liquid reactant(s) and 1,4-dioxane (4 mL) were added through the septum. The septum was replaced with a teflon screwcap. The Schlenk tube was sealed, and the mixture was stirred at the indicated temperature (45-110 °C) for 24h. The reaction mixture was then cooled to room temperature, diluted with dichloromethane (20 mL),

filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to give corresponding the desired *N*-arylpyrrolidone.

# (b) The procedure for the synthesis of benzamide derivatives<sup>2</sup>

Aryl acyl chloride (20 mmol) was added dropwise to a solution of amine (22 mmol), Et<sub>3</sub>N (25 mmol) and dichloromethane (100mL) at room temperature. The reaction mixture was stirred for 12 h at room temperature and then was diluted with dichloromethane. The solution was transferred to a separation funnel and was washed with 1N HCl. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to give corresponding the desired benzamide derivatives.

### (c) The procedure for the synthesis of alkyl amide derivatives<sup>3</sup>

To a solution of amine (20 mmol) in dichloromethane (100 mL) was added Et<sub>3</sub>N (25 mmol). Acyl chloride (22 mmol) was then added dropwise to the mixture at room temperature. The reaction mixture was stirred for 12 h at room temperature and then was diluted with dichloromethane. The solution was transferred to a separation funnel and was washed with 1N HCl. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to give corresponding the desired benzamide derivatives.

### (d) The procedure for the synthesis of (*E*)-*N*-Sulfonyl Amidines

Zn(OTf)<sub>2</sub> (0.02 mmol), amides (0.2 mmol), and sulfamides (0.2 mmol) were added to a 20 mL test tube with a stirring bar. Cyclohexane (1.0 mL), diazo compounds (0.4 mmol) were added via syringe. The reaction mixture was heated in an oil bath at reflux (Tips: severe reflux, recommendation temperature: 90 °C) for 12 h under air (Tips: even if solvent volatilization, still no problem). After, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using petroleum ether/ ethylacetate to give the desired products.

(Tips: In many cases, (*E*)-*N*-Sulfonyl Amidines slightly soluble in ethyl acetate, soluble in dichloromethane)

ÎL .		N <sub>2</sub> cataly	st (10 mol%), solvent (1	mL) N
Ph-N		$R^1 R^2$	air, reflux, 12 h	Ph-N
1a	2a	3		4a
Entry	Catalyst	Diazo (equiv)	Solvent	Yield (%) <sup>b</sup>
1	Cu(OAc) <sub>2</sub>	<b>3a</b> (0.5)	$C_{6}H_{12}$	trace
2	Cu(OAc) <sub>2</sub>	<b>3a</b> (1.0)	C <sub>6</sub> H <sub>12</sub>	9
3	Cu(OAc) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	18
4	Cul	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	19
5	Co(BF <sub>4</sub> ) <sub>2</sub> ·6H <sub>2</sub> O	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	56
6	Rh <sub>2</sub> (OAc) <sub>4</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	25
7	Pd(OAc) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
8	Ag <sub>2</sub> CO <sub>3</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	24
9	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	98
10 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	EA	60
11 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	DCE	66
12 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	<sup>/</sup> PrOH	< 5
13 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	DME	< 5
14 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	PhH	79
15 <sup>c</sup>	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	DMSO	< 5
16	—	<b>3a</b> (2.0)	$C_{6}H_{12}$	< 5
17	Zn(OTf) <sub>2</sub>		C <sub>6</sub> H <sub>12</sub>	< 5
18	Zn(OTf) <sub>2</sub>	<b>3b</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	98
19	Zn(OTf) <sub>2</sub>	<b>3c</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	93
20	Zn(OTf) <sub>2</sub>	<b>3d</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	30
21	Zn(OTf) <sub>2</sub>	<b>3e</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
22	Zn(OTf) <sub>2</sub>	<b>3f</b> (2.0)	$C_6H_{12}$	11
N₂ H 3a, F 3b, F 3c, F	COOR <sub>3</sub> Ph $R_3 = Et$ $R_3 = Pr$ $R_3 = Ph$	N <sub>2</sub> CO <sub>2</sub> Et Me <b>3d</b>	O <sub>2</sub> C CO <sub>2</sub> Me	H TMS

# Table S1. Optimization of the Reaction Conditions<sup>*a*</sup>

<sup>*a*</sup>Conditions: **1a** (0.2 mmol), **2a** (0.2 mmol), **3** (2.0 equiv), catalyst (10 mol%) in  $C_6H_{12}$  was stirred at reflux for 12 h under air. <sup>*b*</sup>Isolated yields. <sup>*c*</sup>80 °C.

°L		o catalys	t (10 mol%), solvent (1 mL)	Ts N
Ph-N +		N <sub>2</sub> OEt	air, reflux, 12 h	Ph-N
1a	2a	3a		4a
entry	catalyst	diazo (equiv)	solvent	yield (%) <sup>[b]</sup>
1	Cu(OAc) <sub>2</sub>	<b>3a</b> (2.0)	$C_6H_{12}$	18
2	Cul	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	19
3	CuO	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
4	Co(acac) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
5	Co(BF <sub>4</sub> ) <sub>2</sub> ·6H <sub>2</sub> O	<b>3a</b> (2.0)	$C_6H_{12}$	56
6	Rh <sub>2</sub> (OAc) <sub>4</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	25
7	Pd(OAc) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
8	Ag <sub>2</sub> CO <sub>3</sub>	<b>3a</b> (2.0)	$C_6H_{12}$	24
9	Zn(OTf) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	98
10	Cu(OTf) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5
11	AgOTf	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	42
12	Ni(OTf) <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	39
13	Bi(OTf) <sub>3</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	62
14	In(OTf) <sub>3</sub>	<b>3a</b> (2.0)	$C_{6}H_{12}$	34
15	Sc(OTf) <sub>3</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	31
16	Mg(OTf) <sub>2</sub>	<b>3a</b> (2.0)	$C_6H_{12}$	60
17	ZnCl <sub>2</sub>	<b>3a</b> (2.0)	$C_6H_{12}$	30
18	Zn(OAc) <sub>2</sub> ·2H <sub>2</sub> O	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	26
19	Znl <sub>2</sub>	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	26
20	$ZnF_2$	<b>3a</b> (2.0)	$C_6H_{12}$	28
21	ZnO	<b>3a</b> (2.0)	C <sub>6</sub> H <sub>12</sub>	< 5

# Table S2. Screening of the Reaction Catalysts<sup>a</sup>

<sup>*a*</sup>Conditions: **1a** (0.2 mmol), **2a** (0.2 mmol), **3a** (0.4 mmol), catalyst (10 mol%) in  $C_6H_{12}$  was stirred at reflux for 12 h under air.



Scheme S1. Mechanistic probes.



Figure S1. The Outcome of EDA.

# **Mechanistic Probes**

# (a) Cyclopropanation experiment (carbene traps experiment):





# (b) Control reaction:



# (c) High-resolution mass spectrometry (HRMS) analysis:



[<sup>18</sup>O]-1a, detected by HRMS



(d) Trapping of intermediate:





# (e) Identify the outcome of EDA:





# (f) NMR study on the model reaction to identify the outcome of EDA:

f(a) <sup>1</sup>H NMR:



f(b) <sup>1</sup>H NMR:



# **Compound Characterizations**



(*E*)-4-Methyl-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4a). Petroleum ether/ ethylacetate = 3:1, white solid, 61.4 mg, 98% yield, mp: 124.5–125.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80–7.78 (m, 2H), 7.48–7.46 (m, 2H), 7.36–7.32 (m, 2H), 7.24–7.18 (m, 3H), 3.88 (t, *J* = 7.2 Hz, 2H), 3.30 (t, *J* = 8.0 Hz, 2H), 2.37 (s, 3H), 2.20–2.12 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 142.1, 140.1, 138.5, 129.1, 128.7, 126.30, 126.27, 122.9, 52.0, 31.9, 21.3, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 315.1162, Found: 315.1169; IR (neat, cm-1):  $\upsilon$ 2917, 2849, 1743, 1536, 1300, 1146, 824, 651.



(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)benzenesulfonamide (4b). Petroleum ether/ ethylacetate = 3:1, white solid, 57.4 mg, 96% yield, mp: 137.3–139.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.92–7.90 (m, 2H), 7.50–7.41 (m, 5H), 7.36–7.32 (m, 2H), 7.22–7.19 (m, 1H), 3.89 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.22–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 142.9, 138.5, 131.6, 128.7, 128.5, 126.4, 126.3, 123.0, 52.1, 32.0, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 301.1005, Found: 301.1011; IR (neat, cm-1):  $\upsilon$  2924, 2852, 1742, 1536, 1300, 1146, 855, 690.



(*E*)-4-Chloro-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4c). Petroleum ether/ ethylacetate = 3:1, white solid, 65.5 mg, 98% yield, mp: 136.3–137.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84–7.82 (m, 2H), 7.45–7.33 (m, 6H), 7.24–7.20 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.33 (t, *J* = 8.0 Hz, 2H), 2.25–2.17 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 141.5, 138.3, 137.8,

128.8, 128.7, 127.8, 126.6, 123.0, 52.2, 32.1, 19.4. HRMS (ESI-TOF): Anal. Calcd. For  $C_{16}H_{15}{}^{35}CIN_2O_2S+Na^+$ : 357.0435,  $C_{16}H_{15}{}^{37}CIN_2O_2S+Na^+$ : 359.0405, Found: 357.0438, 359.0396; IR (neat, cm-1): v 2919, 2849, 1745, 1530, 1298, 1147, 752, 619.



### (E)-N-(1-phenylpyrrolidin-2-ylidene)-4-(trifluoromethyl)benzenesulfonamide

(**4d**). Petroleum ether/ ethylacetate = 3:1, white solid, 67.3 mg, 92% yield, mp: 149.8–151.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.03–8.01 (m, 2H), 7.70–7.68 (m, 2H), 7.44–7.42 (m, 2H), 7.38–7.34 (m, 2H), 7.27–7.22 (m, 1H), 3.94 (t, *J* = 7.2 Hz, 2H), 3.36 (t, *J* = 8.0 Hz, 2H), 2.27 – 2.20 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.9, 146.4, 138.2, 133.24 (q, *J* = 32 Hz), 128.8, 126.84, 126.81, 125.7 (q, *J* = 4 Hz), 123.4 (q, *J* = 271 Hz), 123.2, 52.4, 32.3, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 369.0879, Found: 369.0884; IR (neat, cm-1): v 2919, 2849, 1748, 1547, 1304, 1103, 689.



(*E*)-4-Bromo-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4e). Petroleum ether/ ethylacetate = 3:1, white solid, 70.8 mg, 94% yield, mp: 141.1–142.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.77–7.74 (m, 2H), 7.57–7.55 (m, 2H), 7.44–7.42 (m, 2H), 7.37–7.33 (m, 2H), 7.24–7.20 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.24–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 142.1, 138.3, 131.7, 128.8, 128.0, 126.6, 126.3, 123.1, 52.2, 32.1, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub><sup>79</sup>BrN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 400.9930, C<sub>16</sub>H<sub>15</sub><sup>81</sup>BrN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 402.9909, Found: 400.9941, 402.9943; IR (neat, cm-1): v 2920, 2850, 1737, 1533, 1147, 742, 608.



(*E*)-4-Fluoro-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4f). Petroleum ether/ ethylacetate = 3:1, white solid, 62.1 mg, 98% yield, mp: 108.4–109.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.92–7.89 (m, 2H), 7.46–7.44 (m, 2H), 7.37–7.33 (m, 2H), 7.23–7.20 (m, 1H), 7.13–7.08 (m, 2H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.33 (t, *J* = 8.0 Hz, 2H), 2.25–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 164.4 (d, *J* = 251 Hz), 139.14 (d, *J* = 3 Hz), 138.4, 128.9 (d, *J* = 9 Hz), 128.8, 126.5, 123.0, 115.6 (d, *J* = 23 Hz), 52.2, 32.1, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 341.0730, Found: 341.0740; IR (neat, cm-1): v 2918, 2849, 1748, 1536, 1305, 1148, 844, 671.



(*E*)-4-Methoxy-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4g). Petroleum ether/ ethylacetate = 2:1, white solid, 58.3 mg, 88% yield, mp: 68.2-69.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84–7.82 (m, 2H), 7.48–7.46 (m, 2H), 7.36–7.32 (m, 2H), 7.21–7.17 (m, 1H), 6.92–6.90 (m, 2H), 3.88 (t, *J* = 7.2 Hz, 2H), 3.81 (s, 3H), 3.29 (t, *J* = 8.0 Hz, 2H), 2.20–2.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 162.0, 138.5, 135.0, 128.7, 128.3, 126.2, 122.9, 113.6, 55.4, 52.0, 31.9, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 331.1111, Found: 331.1109; IR (neat, cm-1): v 2923, 2849, 1748, 1546, 1142, 672.



(*E*)-4-(*tert*-butyl)-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4h). Petroleum ether/ ethylacetate = 3:1, white solid, 66.4 mg, 94% yield, mp: 113.9–115.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84–7.82 (m, 2H), 7.50–7.49 (m, 2H), 7.46–7.44 (m, 2H), 7.37–7.33 (m, 2H), 7.22–7.18 (m, 1H), 3.89 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.21–2.14 (m, 2H), 1.31 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 155.1, 140.0, 138.6, 128.7, 126.3, 126.1, 125.5, 122.9, 52.0, 34.9, 32.0, 31.0, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 379.1451, Found: 379.1464; IR (neat, cm-1): v 2961, 2923, 1749, 1551, 1150, 760, 628.



(*E*)-4-Iodo-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4i). Petroleum ether/ ethylacetate = 3:1, white solid, 81.5 mg, 96% yield, mp: 132.7–133.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.78–7.76 (m, 2H), 7.62–7.60 (m, 2H), 7.44–7.42 (m, 2H), 7.37–7.33 (m, 2H), 7.23–7.20 (m, 1H), 3.90 (t, *J* = 7.2 Hz, 2H), 3.31 (t, *J* = 8.0 Hz, 2H), 2.23–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 142.7, 138.3, 137.6, 128.8, 127.9, 126.6, 123.0, 98.6, 52.2, 32.1, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub>IN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 448.9791, Found: 448.9798; IR (neat, cm-1):  $\upsilon$ 3043, 2941, 1736, 1532, 1298, 1148, 737.



(*E*)-2-Methyl-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4j). Petroleum ether/ ethylacetate = 3:1, white solid, 61.4 mg, 98% yield, mp: 118.7–119.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.02–8.01 (m, 1H), 7.45–7.44 (m, 2H), 7.38–7.32 (m, 3H), 7.26–7.19 (m, 3H), 3.87 (t, *J* = 7.2 Hz, 2H), 3.30 (t, *J* = 8.0 Hz, 2H), 2.61 (s, 3H), 2.21–2.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.8, 140.8, 138.5, 137.4, 132.0, 131.7, 128.7, 127.5, 126.5, 125.4, 123.2, 52.1, 32.0, 20.3, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 315.1162, Found: 315.1168; IR (neat, cm-1): v 2923, 2852, 1745, 1558, 1273, 1115, 692.



**Methyl** (*E*)-2-(*N*-(1-phenylpyrrolidin-2-ylidene)sulfamoyl)benzoate (4k). Petroleum ether/ ethylacetate = 2:1, white solid, 41.7 mg, 59% yield, mp: 117.4–118.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09–8.06 (m, 1H), 7.54–7.51 (m, 3H), 7.47–7.45 (m, 2H), 7.35–7.31 (m, 2H), 7.22–7.18 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.74 (s, 3H), 3.28 (t, *J* = 8.0 Hz, 2H), 2.23–2.16 (m, 2H). <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>) δ 169.0, 168.1, 140.7, 138.4, 131.6, 131.4, 130.3, 128.7, 128.7, 128.3, 126.5, 123.3, 52.6, 52.3, 32.3, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S+H<sup>+</sup>: 359.1060, Found: 359.1063; IR (neat, cm-1): v 2920, 2850, 1732, 1542, 1289, 1152, 759.



(*E*)-2-nitro-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4l). Petroleum ether/ ethylacetate = 3:1, light yellow solid, 68.1 mg, 99% yield, mp: 104.5–107.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.17– 8.13 (m, 1H), 7.65–7.55 (m, 3H), 7.39–7.37 (m, 2H), 7.34–7.30 (m, 2H), 7.22–7.18 (m, 1H), 3.93 (t, *J* = 7.2 Hz, 2H), 3.37 (t, *J* = 8.0 Hz, 2H), 2.28–2.20 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.2, 147.5, 138.1, 135.7, 132.5, 131.9, 129.6, 128.8, 126.9, 124.1, 123.6, 52.7, 32.9, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S+H<sup>+</sup>: 346.0856, Found: 346.0864; IR (neat, cm-1): v 2923, 2852, 1745, 1531, 1300, 1149, 733.



(*E*)-2-bromo-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4m). Petroleum ether/ ethylacetate = 3:1, white solid, 66.9 mg, 89% yield, mp: 107.1–108.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.17–8.15 (m, 1H), 7.68–7.66 (m, 1H), 7.50–7.48 (m, 2H), 7.37–7.27 (m, 4H), 7.20–7.16 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.38 (t, *J* = 8.0 Hz, 2H), 2.24–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.1, 141.5, 138.3, 134.9, 132.7, 129.7, 128.7, 127.2, 126.5, 123.3, 120.3, 52.3, 32.7, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub><sup>79</sup>BrN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 400.9930, C<sub>16</sub>H<sub>15</sub><sup>81</sup>BrN<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 402.9909, Found: 400.9941, 402.9945; IR (neat, cm-1): v 2921, 2850, 1736, 1532, 1300, 1146, 740.



(*E*)-3-Nitro-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4n). Petroleum ether/ ethylacetate = 3:1, white solid, 68.5 mg, 99% yield, mp: 132.7–133.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.74–8.73 (m, 1H), 8.33–8.30 (m, 1H), 8.22–8.20 (m, 1H), 7.66–7.62 (m, 1H), 7.44–7.36 (m, 4H), 7.27–7.23 (m, 1H), 3.97 (t, *J* = 7.2 Hz, 2H), 3.39 (t, *J* = 8.0 Hz, 2H), 2.31–2.23 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.0, 147.8, 145.1, 138.0, 131.9, 129.9, 128.9, 127.0, 126.0, 123.3, 121.7, 52.5, 32.4, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S+H<sup>+</sup>: 346.0856, Found: 346.0859; IR (neat, cm-1): v 2920, 2850, 1749, 1528, 1306, 1154, 661.



(*E*)-3-Bromo-*N*-(1-phenylpyrrolidin-2-ylidene)benzenesulfonamide (4o). Petroleum ether/ ethylacetate = 20:1, white solid, 74.7 mg, 99% yield, mp: 109.2–110.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (s, 1H), 7.83–7.81 (m, 1H), 7.61–7.59 (m, 1H), 7.45–7.43 (m, 2H), 7.39–7.35 (m, 2H), 7.33–7.29 (m, 1H), 7.25–7.21 (m, 1H), 3.92 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.25–2.17 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.8, 144.8, 138.2, 134.6, 130.1, 129.4, 128.8, 126.7, 124.8, 123.1, 122.3, 52.3, 32.2, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>15</sub><sup>79</sup>BrN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 379.0110, C<sub>16</sub>H<sub>15</sub><sup>81</sup>BrN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 381.0090, Found: 371.0109, 381.0100; IR (neat, cm-1): v 2920, 2850, 1747, 1546, 1305, 1149, 654.



(*E*)-*N*-(1-phenylpyrrolidin-2-ylidene)naphthalene-2-sulfonamide (4p). Petroleum ether/ ethylacetate = 2:1, white solid, 62.6 mg, 90% yield, mp: 180.9–182.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 (s, 1H), 7.91–7.84 (m, 4H), 7.59 – 7.52 (m, 2H), 7.47–7.45 (m, 2H), 7.35–7.31 (m 2H), 7.21–7.17 (m, 1H), 3.87 (t, *J* = 7.2 Hz, 2H), 3.35 (t, *J* = 8.0 Hz, 2H), 2.20–2.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.6, 139.9, 138.4, 134.3, 132.0, 129.1, 128.8, 128.7, 128.1, 127.7, 127.0, 126.7, 126.4, 123.0, 122.6, 52.1, 32.1, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 351.1162, Found: 351.1163; IR (neat, cm-1): υ 2920, 2849, 1733, 1560, 1267, 1139, 671.



(*E*)-*N*-(1-phenylpyrrolidin-2-ylidene)quinoline-8-sulfonamide (4q). Petroleum ether/ ethylacetate = 1:2, light yellow solid, 50.7 mg, 72% yield, mp: 173.5–175.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.08–9.07 (m, 1H), 8.55–8.53 (m, 1H), 8.22–8.20 (m, 1H), 7.98–7.96 (m, 1H), 7.60–7.56 (m, 1H), 7.50–7.47 (m, 1H), 7.38–7.37 (m, 2H), 7.17–7.13 (m, 2H), 7.08–7.04 (m, 1H), 3.93 (t, J = 7.2 Hz, 2H), 3.70 (t, J = 7.9 Hz, 2H), 2.32–2.25 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.6, 150.7, 147.5, 144.0, 138.7, 136.4, 132.7, 130.3, 128.9, 128.5, 126.0, 125.4, 122.9, 121.5, 52.1, 32.8, 19.9. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S+Na<sup>+</sup>: 374.0934, Found: 374.0932; IR (neat, cm-1): v 2959, 2921, 2852, 1733, 1544, 1277, 1138, 609.



(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)thiophene-2-sulfonamide (4r). Petroleum ether/ ethylacetate = 20:1, white solid, 60.7 mg, 99% yield, mp: 112.3–113.5 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59–7.58 (m, 1H), 7.50–7.46 (m, 3H), 7.39–7.35 (m, 2H), 7.25–7.21 (m, 1H), 7.0– 6.98 (m, 1H), 3.91 (t, J = 7.2 Hz, 2H), 3.32 (t, J = 8.0 Hz, 2H), 2.23–2.15 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.8, 144.5, 138.2, 130.4, 130.1, 128.8, 126.7, 126.6, 123.1, 52.3, 32.0, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub>+Na<sup>+</sup>: 329.0389, Found: 329.0398; IR (neat, cm-1): v 3094, 2901, 1539, 1292, 1138, 722.

(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)cyclopropanesulfonamide (4s). Petroleum ether/ ethylacetate = 2:1, white solid, 52.2 mg, 99% yield, mp: 69.4–70.7 °C. <sup>1</sup>H NMR (400 MHz,

CDCl<sub>3</sub>)  $\delta$  7.55–7.53 (m, 2H), 7.41–7.37 (m, 2H), 7.28–7.21 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.57–2.49 (m, 1H), 2.24–2.16 (m, 2H), 1.16–1.12 (m, 2H), 0.94–0.89 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.2, 138.7, 128.7, 126.1, 122.8, 51.9, 32.2, 31.8, 19.5, 5.1. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 265.1005, Found: 265.1018; IR (neat, cm-1):  $\upsilon$  2923, 2851, 1750, 1549, 1272, 1136, 733.



(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)methanesulfonamide (4t) Petroleum ether/ ethylacetate = 2:1, white solid, 41.2 mg, 87% yield, mp: 103.0–103.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.51–7.49 (m, 2H), 7.41–7.38 (m, 2H), 7.28–7.22 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.33 (t, *J* = 8.0 Hz, 2H), 2.98 (s, 3H), 2.25–2.18 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.3, 138.6, 128.7, 126.3, 123.0, 52.0, 42.6, 32.0, 19.6. HRMS (ESI-TOF): Anal. Calcd. For C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 261.0668, Found: 261.0679; IR (neat, cm-1): v 2920, 2850, 1746, 1555, 1270, 1131, 759.



(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)butane-1-sulfonamide (4u). Petroleum ether/ ethylacetate = 3:1, white solid, 51.8 mg, 93% yield, mp: 68.0–69.1 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.51–7.49 (m, 2H), 7.41–7.37 (m, 2H), 7.25–7.22 (m, 1H), 3.91 (t, *J* = 7.2 Hz, 2H), 3.34 (t, *J* = 8.0 Hz, 2H), 3.02 (t, *J* = 8.0 Hz, 2H), 2.25–2.17 (m, 2H), 1.85–1.77 (m, 2H), 1.47–1.37 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 138.6, 128.6, 126.2, 122.9, 54.2, 51.8, 32.1, 25.6, 21.4, 19.6, 13.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 281.1318, Found: 281.1319; IR (neat, cm-1): v 2955, 2918, 1749, 1562, 1263, 1129, 860, 695.



# (*E*)-1-Phenyl-*N*-(1-phenylpyrrolidin-2-ylidene)methanesulfonamide(4v).Petroleum ether/ ethylacetate = 2:1, white solid, 55.7 mg, 89% yield, mp: 128.7–129.9 °C. <sup>1</sup>H NMR(400 MHz, CDCl<sub>3</sub>) $\delta$ 7.41 – 7.25 (m, 10H), 4.21 (s, 2H), 3.80 (t, *J* = 7.2 Hz, 2H), 3.06 (t, *J* = 7.9 Hz,2H), 2.08–2.01 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) $\delta$ 169.2, 138.4, 131.0, 130.3, 128.6, 128.1,128.0, 126.4, 123.3, 60.2, 52.0, 32.0, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>:337.0981, Found: 337.0993; IR (neat, cm-1): v 2920, 2849, 1735, 1566, 1099, 690.



*p*-Tolyl (*E*)-(1-phenylpyrrolidin-2-ylidene)sulfamate (4w). Petroleum ether/ ethylacetate = 4:1, white solid, 53.9 mg, 82% yield, mp: 75.7–76.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.37–7.34 (m, 4H), 7.30–7.25 (m, 1H), 7.16–7.09 (m, 4H), 3.93 (t, *J* = 7.2 Hz, 2H), 3.25 (t, *J* = 8.0 Hz, 2H), 2.32 (s, 3H), 2.22–2.15 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.7, 148.6, 138.0, 136.0, 129.7, 128.8, 127.0, 123.5, 122.0, 52.9, 32.2, 20.8, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S+Na<sup>+</sup>: 353.0930, Found: 353.0937; IR (neat, cm-1): v 2917, 2848, 1700, 1557, 1146, 826.



*N*,*N*-Dimethyl (*E*)-(1-phenylpyrrolidin-2-ylidene)sulfamate (4x). Petroleum ether/ ethylacetate = 4:1, colourless liquid, 33.4 mg, 63% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.56–7.54 (m, 2H), 7.41–7.37 (m, 2H), 7.24–7.21 (m, 1H), 3.93 (t, *J* = 7.1 Hz, 2H), 3.30 (t, *J* = 8.0 Hz, 2H), 2.72 (s, 6H), 2.25–2.17 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.5, 138.9, 128.6, 126.0, 122.8, 52.0, 38.9, 32.0, 19.6. HRMS (ESI-TOF): Anal. Calcd. For C<sub>12</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S+Na<sup>+</sup>: 290.0934, Found: 290.0924; IR (neat, cm-1): v 2961, 2878, 1749, 1563, 1302, 1138, 712.



(*E*)-1-(Benzo[*d*]isoxazol-3-yl)-*N*-(1-phenylpyrrolidin-2-ylidene)methanesulfonami de (5a). Petroleum ether/ ethylacetate = 2:1, white solid, 46.6 mg, 66% yield, mp: 126.9–128.0 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.78 (m, 1H), 7.58–7.50 (m, 2H), 7.38–7.32 (m, 4H), 7.26–7.19 (m, 2H), 4.71 (s, 2H), 3.83 (t, *J* = 7.2 Hz, 2H), 3.15 (t, *J* = 8.0 Hz, 2H), 2.13–2.05 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.1, 163.5, 150.3, 138.1, 129.9, 128.8, 126.8, 123.8, 123.3, 122.9, 121.0, 109.6, 52.3, 51.3, 32.3, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S+Na<sup>+</sup>: 378.0883, Found: 378.0871; IR (neat, cm-1): v 2921, 2850, 1748, 1557, 1294, 860, 749.



(*E*)-*N*-(1-Phenylpyrrolidin-2-ylidene)-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyraz ol-1-yl)benzenesulfonamide (5b). Petroleum ether/ ethylacetate = 3:1, white solid, 95.8 mg, 90% yield, mp: 171.7–172.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.90–7.88 (m, 2H), 7.43–7.38 (m, 4H), 7.36–7.32 (m, 2H), 7.26–7.21 (m, 1H), 7.16–7.14 (m, 2H), 7.10–7.08 (m, 2H), 6.72 (s, 1H), 3.92 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 7.9 Hz, 2H), 2.36 (s, 3H), 2.25–2.17 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 145.0, 142.6, 141.5, 139.5, 138.2, 129.6, 128.8, 128.6, 127.4, 126.6, 125.6, 125.1, 123.1, 105.9, 52.3, 32.1, 21.2, 19.4. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -62.35. HRMS (ESI-TOF): Anal. Calcd. For C<sub>27</sub>H<sub>23</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S+Na<sup>+</sup>: 547.1386, Found: 347.1398; IR (neat, cm-1): v 3141, 2922, 2852, 1741, 1550, 1147, 968,636.



((3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-*b*:4' ,5'-*d*]pyran-3a-yl)methyl ((*E*)-1-phenylpyrrolidin-2-ylidene)sulfamate (5c). Petroleum ether/ ethylacetate = 3:1, colorless sticky liquid, 94.1 mg, 98% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.51–7.49 (m, 2H), 7.40–7.36 (m, 2H), 7.26-7.23 (m, 1H), 4.55 (dd, *J* = 7.8, 2.2 Hz, 1H), 4.38 (d, *J* = 1.7 Hz, 1H), 4.22 (d, *J* = 8.2 Hz, 1H), 4.17 (d, *J* = 4.7 Hz, 2H), 3.96 (t, *J* = 7.2 Hz, 2H), 3.89 (d, *J* = 12.9 Hz, 1H), 3.73 (d, *J* = 13.0 Hz, 1H), 3.31 (t, *J* = 7.9 Hz, 2H), 2.26–2.19 (m, 2H), 1.52 (s, 3H), 1.40 (s, 3H), 1.39 (s, 3H), 1.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.4, 138.1, 128.8, 126.7, 123.2, 108.9, 108.8, 101.0, 70.6, 69.9, 69.4, 61.1, 52.8, 32.0, 26.4, 25.7, 25.1, 23.9, 19.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>8</sub>S+Na<sup>+</sup>: 505.1615, Found: 505.1616; IR (neat, cm-1):  $\upsilon$  2988, 2934, 1557, 1156, 862, 606.



(*E*)-*N*-(1-(4-fluorophenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (6a). Petroleum ether/ ethylacetate = 3:1, light yellow solid, 65.9 mg, 99% yield, mp: 128.2–129.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.78–7.76 (m, 2H), 7.46–7.41 (m, 2H), 7.27–7.23 (m, 2H), 7.06–7.00 (m, 2H), 3.86 (t, *J* = 7.2 Hz, 2H), 3.29 (t, *J* = 8.0 Hz, 2H), 2.38 (s, 3H), 2.22–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.7, 160.4 (d, *J* = 245 Hz), 142.2, 134.0, 134.54 (d, *J* = 4 Hz), 129.1, 126.3, 124.9 (d, *J* = 8 Hz), 115.6 (d, *J* = 22 Hz), 52.2, 31.8, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 333.1068, Found: 333.1058; IR (neat, cm-1): v 2920, 2850, 1738, 1503, 1146, 824, 656.



### (E)-N-(1-(4-chlorophenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide

(**6b**). Petroleum ether/ ethylacetate = 3:1, white solid, 65.8 mg, 95% yield, mp: 142.5–143.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79–7.77 (m, 2H), 7.46–7.42 (m, 2H), 7.3–7.27 (m, 2H), 7.26–7.24 (m, 2H), 3.86 (t, *J* = 7.2 Hz, 2H), 3.30 (t, *J* = 8.0 Hz, 2H), 2.39 (s, 3H), 2.22–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 142.3, 139.8, 137.1, 131.5, 129.2, 128.8, 126.3, 124.0, 51.8, 31.9, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>17</sub><sup>35</sup>ClN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 349.0772, C<sub>17</sub>H<sub>17</sub><sup>37</sup>ClN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 351.0743, Found: 349.0767, 351.0762; IR (neat, cm-1): v 2920, 2850, 1721, 1545, 1145, 831, 658.



### (E)-N-(1-(4-bromophenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide

(6c). Petroleum ether/ ethylacetate = 3:1, white solid, 78.1 mg, 99% yield, mp: 147.1–148.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79–7.78 (m, 2H), 7.45–7.43 (m, 2H), 7.39–7.37 (m, 2H), 7.26–7.24 (m, 2H), 3.85 (t, *J* = 7.2 Hz, 2H), 3.30 (t, *J* = 8.0 Hz, 2H), 2.39 (s, 3H), 2.21–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 142.4, 139.8, 137.6, 131.7, 129.2, 126.3, 124.3, 119.3, 51.7, 31.9, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>17</sub><sup>79</sup>BrN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 393.0267, C<sub>17</sub>H<sub>17</sub><sup>81</sup>BrN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 395.0246, Found: 393.0256, 395.0251; IR (neat, cm-1): v 2918, 2849, 1716, 1297, 1144, 827.



# (E)-4-methyl-N-(1-(p-tolyl)pyrrolidin-2-ylidene)benzenesulfonamide (6d).

Petroleum ether/ ethylacetate = 3:1, white solid, 65.0 mg, 99% yield, mp: 75.8–76.7 °C. <sup>1</sup>H NMR

(400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79–7.77 (m, 2H), 7.35–7.33 (m, 2H), 7.24–7.21 (m, 2H), 7.15–7.13 (m, 2H), 3.85 (t, *J* = 7.2 Hz, 2H), 3.28 (t, *J* = 8.0 Hz, 2H), 2.37 (s, 3H), 2.31 (s, 3H), 2.19–2.11 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 142.0, 140.2, 136.2, 136.0, 129.2, 129.1, 126.3, 122.8, 52.1, 31.9, 21.3, 20.9, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 329.1318, Found: 329.1319; IR (neat, cm-1): v 2921, 2853, 1708, 1540, 1147, 815, 665.



### (E)-N-(1-(4-methoxyphenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide

(**6e**). Petroleum ether/ ethylacetate = 2:1, white solid, 67.9 mg, 99% yield, mp: 111.2–112.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79–7.77 (m, 2H), 7.38–7.35 (m, 2H), 7.24–7.22 (m, 2H), 6.88–6.84 (m, 2H), 3.84 (t, *J* = 7.2 Hz, 2H), 3.78 (s, 3H), 3.28 (t, *J* = 8.0 Hz, 2H), 2.38 (s, 3H), 2.20–2.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 157.7, 142.0, 140.3, 131.5, 129.1, 126.3, 124.5, 113.9, 55.4, 52.4, 31.8, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 345.1267, Found: 345.1279; IR (neat, cm-1): v 2924, 2851, 1707, 1146, 834, 666.



(*E*)-*N*-(1-(4-cyanophenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (6f). Petroleum ether/ ethylacetate = 2:1, white solid, 67.3 mg, 99% yield, mp: 161.4–162.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80–7.78 (m, 2H), 7.71–7.68 (m, 2H), 7.62–7.59 (m, 2H), 7.28–7.26 (m, 2H), 3.93 (t, *J* = 7.2 Hz, 2H), 3.35 (t, *J* = 8.0 Hz, 2H), 2.41 (s, 3H), 2.26–2.18 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.8, 142.8, 142.4, 139.4, 132.6, 129.3, 126.4, 122.4, 118.2, 108.8, 51.3, 32.1, 21.4, 19.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S+H<sup>+</sup>: 340.1114, Found: 340.1132; IR (neat, cm-1): v 2921, 2852, 2222, 1299, 1149, 836, 665.



# (E) - N - (1 - (4 - (tert- butyl) phenyl) pyrrolidin-2-ylidene) - 4 - methylbenzenesulfonamide

**(6g).** Petroleum ether/ ethylacetate = 3:1, white solid, 56.8 mg, 77% yield, mp: 138.3–140.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–8.79 (m, 2H), 7.42–7.40 (m, 2H), 7.36–7.34 (m, 2H), 7.25–7.23 (m, 2H), 3.87 (t, *J* = 7.2 Hz, 2H), 3.28 (t, *J* = 8.0 Hz, 2H), 2.38 (s, 3H), 2.19–2.11 (m, 2H), 1.30 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.5, 149.2, 142.1, 140.2, 135.9, 129.1, 126.4, 125.6, 122.4, 52.1, 34.4, 31.9, 31.2, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 371.1788, Found: 371.1783; IR (neat, cm-1): v 2947, 2862, 1709, 1539, 1301, 1150, 656.



(*E*)-4-methyl-*N*-(1-(4-(trifluoromethoxy)phenyl)pyrrolidin-2-ylidene)benzenesulf onamide (6h). Petroleum ether/ ethylacetate = 3:1, white solid, 43.6 mg, 55% yield, mp: 131.2–132.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79–7.77 (m, 2H), 7.55–7.52 (m, 2H), 7.27–7.24 (m, 2H), 7.20–7.18 (m, 2H), 3.89 (t, *J* = 7.2 Hz, 2H), 3.32 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.24–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.8, 142.5, 139.8, 137.1, 129.2, 126.4, 124.2, 121.2, 52.0, 31.9, 21.4, 19.4. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -57.96. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S+Na<sup>+</sup>: 421.0804, Found: 421.0800; IR (neat, cm-1): v 2924, 2853, 1713, 1551, 1147, 674.



**Methyl** (*E*)-4-(2-(tosylimino)pyrrolidin-1-yl)benzoate (6i). Petroleum ether/ ethylacetate = 3:1, white solid, 39.2 mg, 53% yield, mp: 122.6–123.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.01–7.99 (m, 2H), 7.81–7.79 (m, 2H), 7.63–7.61 (m, 2H), 7.27–7.25 m, 2H), 3.94 (t, *J* = 7.2 Hz, 2H), 3.90 (s, 3H), 3.36 (t, *J* = 7.9 Hz, 2H), 2.40 (s, 3H), 2.25–2.18 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 166.2, 142.5, 142.5, 139.7, 130.1, 129.2, 127.2, 126.4, 121.9, 52.1, 51.6, 32.2, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S+H<sup>+</sup>: 373.1217, Found: 373.1223; IR (neat, cm-1):  $\nu$  2922, 2852, 1710, 1278, 1148, 664.



(*E*)-4-methyl-*N*-(1-(4-(methylsulfonyl)phenyl)pyrrolidin-2-ylidene)benzenesulfon amide (6j). Petroleum ether/ ethylacetate = 1:1, white solid, 63.0 mg, 81% yield, mp:  $181.0-182.8 \circ C. {}^{1}H NMR (400 MHz, CDCl_3) \delta 7.89-7.87 (m, 2H), 7.81-7.79 (m, 2H), 7.76-7.74 (m, 2H), 7.29-7.27 (m, 2H), 3.95 (t,$ *J*= 7.1 Hz, 2H), 3.36 (t,*J* $= 7.9 Hz, 2H), 3.03 (s, 3H), 2.41 (s, 3H), 2.27-2.19 (m, 2H). {}^{1}C NMR (100 MHz, CDCl_3) \delta 169.0, 143.2, 142.8, 139.4, 136.9, 129.3, 128.0, 126.3, 122.6, 51.5, 44.4, 32.0, 21.4, 19.3. HRMS (ESI-TOF): Anal. Calcd. For$ C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub>+H<sup>+</sup>: 393.0937, Found: 393.0942; IR (neat, cm-1): v 2922, 2852, 1709, 1548, 1144, 698



(E)-4-methyl-N-(1-(m-tolyl)pyrrolidin-2-ylidene)benzenesulfonamide(6k).Petroleum ether/ ethylacetate = 3:1, white solid, 65.0 mg, 99% yield, mp: 95.0–96.4 °C. <sup>1</sup>H NMR(400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80–7.78 (m, 2H), 7.27–7.20 (m, 5H), 7.02–7.01 (m, 1H), 3.86 (t, J = 7.2 Hz,2H), 3.29 (t, J = 8.0 Hz, 2H), 2.37 (s, 3H), 2.31 (s, 3H), 2.20–2.12 (m, 2H). <sup>13</sup>C NMR (100 MHz,CDCl<sub>3</sub>)  $\delta$  168.4, 142.0, 140.2, 138.5, 138.4, 129.0, 128.5, 127.1, 126.2, 123.7, 120.0, 52.1, 31.9,

21.3, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 329.1318, Found: 329.1306; IR (neat, cm-1): υ 2921, 2853, 1752, 1546, 1144, 669.



(*E*)-4-methyl-*N*-(1-(3-(trifluoromethyl)phenyl)pyrrolidin-2-ylidene)benzenesulfo namide (6l). Petroleum ether/ ethylacetate = 3:1, colorless sticky liquid, 61.3 mg, 80% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87 (s, 1H), 7.80 (d, *J* = 8.2 Hz, 2H), 7.64 (d, *J* = 7.6 Hz, 1H), 7.49–7.42 (m, 2H), 7.26–7.24 (m, 2H), 3.92 (t, *J* = 7.2 Hz, 2H), 3.37 (t, *J* = 8.0 Hz, 2H), 2.39 (s, 3H), 2.26–2.18 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.5, 142.5, 139.8, 139.1, 131.0 (q, *J* = 32 Hz), 129.3, 129.2, 127.65 (q, *J* = 271 Hz), 126.2, 125.4, 122.5 (q, *J* = 4 Hz), 119.7 (q, *J* = 4 Hz), 51.5, 32.0, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 383.1036, Found: 383.1044; IR (neat, cm-1):  $\upsilon$  2922, 2851, 1558, 1327, 1146, 691.



(*E*)-4-methyl-*N*-(1-(2-nitrophenyl)pyrrolidin-2-ylidene)benzenesulfonamide (6m). Petroleum ether/ ethylacetate = 1:1, yellow solid, 69.9 mg, 98% yield, mp: 187.5–189.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.96–7.94 (m, 1H), 7.66–7.64 (m, 3H), 7.47–7.44 (m, 1H), 7.34–7.32 (m, 1H), 7.24–7.22 (m, 2H), 3.89 (t, *J* = 7.1 Hz, 2H), 3.18 (t, *J* = 7.9 Hz, 2H), 2.39 (s, 3H), 2.32–2.24 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.1, 145.4, 142.4, 139.2, 134.3, 131.8, 129.0, 128.5, 126.4, 125.6, 125.4, 52.8, 30.9, 21.4, 20.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S+H<sup>+</sup>: 360.1013, Found: 360.1001; IR (neat, cm-1): v 2922, 2852, 1698, 1527, 1144, 666.



## (E) - N - (1 - (2 - methoxy phenyl) pyrrolidin - 2 - ylidene) - 4 - methyl benzenesulfonamide

(**6n**). Petroleum ether/ ethylacetate = 2:1, white solid, 55.3 mg, 81% yield, mp: 150.0–151.5 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.72–7.70 (m, 2H), 7.30–7.25 (m, 1H), 7.20–7.15 (m, 3H), 6.96–6.91 (m, 2H), 3.76–3.72 (m, 5H), 3.20 (t, *J* = 8.0 Hz, 2H), 2.36 (s, 3H), 2.22–2.15 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.7, 154.1, 141.7, 140.5, 129.4, 128.9, 128.2, 126.6, 126.2, 120.6, 112.0, 55.4, 52.0, 30.9, 21.3, 20.0. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 345.1267, Found: 345.1264; IR (neat, cm-1): v 2918, 2848, 1749, 1557, 1145, 751, 668.



(*E*)-4-methyl-*N*-(1-(o-tolyl)pyrrolidin-2-ylidene)benzenesulfonamide (60). Petroleum ether/ ethylacetate = 2:1, white solid, 49.7 mg, 76% yield, mp: 125.1–126.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.69–7.67 (m, 2H), 7.22–7.17 (m, 5H), 7.07–7.05 (m, 1H), 3.71 (t, *J* = 7.2 Hz, 2H), 3.25 (t, *J* = 8.0 Hz, 2H), 2.35 (s, 3H), 2.26–2.19 (m, 2H), 2.11 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.9, 141.9, 140.3, 137.0, 134.9, 131.1, 129.0, 128.4, 126.8, 126.3, 126.2, 52.9, 30.9, 21.3, 20.2, 17.7. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 329.1318, Found: 329.1307; IR (neat, cm-1): v 2920, 2850, 1751, 1283, 1149, 668.



(*E*)-*N*-(1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)pyrrolidin-2-ylidene)-4-methylben zenesulfonamide (6p). Petroleum ether/ ethylacetate = 2:1, white solid, 73.5 mg, 99% yield, mp: 153.2–155.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80–7.78 (m, 2H), 7.25–7.22 (m, 2H), 6.99– 6.97 (m, 1H), 6.94–6.91 (m, 1H), 6.82–6.79 (m, 1H), 4.22 (s, 4H), 3.81 (t, *J* = 7.2 Hz, 2H), 3.25 (t, *J* = 8.0 Hz, 2H), 2.38 (s, 3H), 2.18–2.10 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 143.2, 142.0, 142.0, 140.2, 131.9, 129.1, 126.3, 117.0, 116.5, 112.6, 64.2, 52.4, 31.8, 21.3, 19.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S+H<sup>+</sup>: 373.1217, Found: 373.1214; IR (neat, cm-1):  $\upsilon$ 2919, 2850, 1749, 1506, 1273, 1145, 662.



(*E*)-*N*-(1-(3,5-dimethylphenyl)pyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (6q). Petroleum ether/ ethylacetate = 3:1, white solid, 67.6 mg, 99% yield, mp: 59.1–60.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.81–7.79 (m, 2H), 7.24–7.22 (m, 2H), 7.06 (s, 2H), 6.85 (s, 1H), 3.85 (t, *J* = 7.2 Hz, 2H), 3.28 (t, *J* = 8.0 Hz, 2H), 2.38 (s, 3H), 2.27 (s, 6H), 2.19–2.12 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 142.0, 140.4, 138.3, 138.3, 129.0, 128.1, 126.2, 120.9, 52.2, 31.9, 21.3, 21.2, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 343.1475, Found: 343.1473; IR (neat, cm-1):  $\upsilon$  2917, 2849, 1748, 1549, 1144, 668.



(*E*)-4-methyl-*N*-(1-(3,4,5-trimethoxyphenyl)pyrrolidin-2-ylidene)benzenesulfona mide (6r). Petroleum ether/ ethylacetate = 1:1, white solid, 67.2 mg, 84% yield, mp: 151.6–152.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82–7.80 (m, 2H), 7.25–7.23 (m, 2H), 6.73 (s, 2H), 3.90 (t, *J* = 7.2 Hz, 2H), 3.81 (s, 3H), 3.70 (s, 6H), 3.35 (t, *J* = 8.0 Hz, 2H), 2.39 (s, 3H), 2.24–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.1, 152.8, 142.2, 140.2, 136.1, 134.3, 129.0, 126.3, 100.7, 60.8, 55.9, 52.2, 32.1, 21.3, 19.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S+H<sup>+</sup>: 405.1479, Found: 405.1480; IR (neat, cm-1): υ 2919, 2848, 1558, 1120, 665.



## (E)-4-methyl-N-(1-(naphthalen-2-yl)pyrrolidin-2-ylidene)benzenesulfonamide

(6s). Petroleum ether/ ethylacetate = 2:1, white solid, 72.0 mg, 99% yield, mp: 116.5–117.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82–8.77 (m, 5H), 7.75–7.72 (m, 1H), 7.69–7.66 (m, 1H), 7.48–7.42 (m, 2H), 7.22–7.20 (m, 2H), 3.94 (t, *J* = 7.2 Hz, 2H), 3.34 (t, *J* = 8.0 Hz, 2H), 2.35 (s, 3H), 2.21–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 142.1, 140.1, 136.1, 133.0, 131.4, 129.1, 128. 4, 127.7, 127.5, 126.5, 126.3, 126.1, 121.7, 120.8, 52.2, 32.0, 21.3, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 365.1318, Found: 365.1314; IR (neat, cm-1): v 2919, 2849, 1714, 1549, 1146, 706.



(*E*)-4-methyl-*N*-(1-(thiophen-3-yl)pyrrolidin-2-ylidene)benzenesulfonamide (6t). Petroleum ether/ ethylacetate = 3:1, white solid, 61.9 mg, 97% yield, mp: 136.2–137.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.85–7.83 (m, 2H), 7.53–7.52 (m, 1H), 7.38–7.36 (m, 1H), 7.28–7.23 (m, 3H), 3.91 (t, *J* = 7.3 Hz, 2H), 3.29 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.22–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  166.9, 142.3, 140.0, 136.8, 129.2, 126.4, 124.6, 121.3, 113.2, 51.6, 31.7, 21.4, 19.2. HRMS (ESI-TOF): Anal. Calcd. For C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub>+H<sup>+</sup>: 321.0726, Found: 321.0736; IR (neat, cm-1): v 2919, 2850, 1736, 1521, 1279, 666.



(*E*)-4-methyl-*N*-(1-(thiophen-2-yl)pyrrolidin-2-ylidene)benzenesulfonamide (6u). Petroleum ether/ ethylacetate = 3:1, white solid, 57.3 mg, 90% yield, mp: 136.3–137.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.85–7.83 (m, 2H), 7.53–7.52 (m, 1H), 7.38–7.36 (m, 1H), 7.28–7.23 (m, 3H), 3.91 (t, *J* = 7.4 Hz, 2H), 3.29 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.22–2.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  166.9, 142.3, 140.0, 136.8, 129.2, 126.4, 124.6, 121.3, 113.2, 51.6, 31.7, 21.4, 19.1. HRMS (ESI-TOF): Anal. Calcd. For C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub>+H<sup>+</sup>: 321.0726, Found: 321.0727; IR (neat, cm-1): v 2921, 2852, 1736, 1520, 1279, 666.



Ethyl (*R*,*E*)-1-phenyl-5-(tosylimino)pyrrolidine-2-carboxylate (7a). Petroleum ether/ ethylacetate = 3:1, white solid, 74.7 mg, 97% yield, mp: 120.6–121.5 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.76–7.74 (m, 2H), 7.34–7.33 (m, 4H), 7.23–7.21 (m, 3H), 4.74–4.70 (m, 1H), 4.17–4.05 (m, 2H), 3.47–3.39 (m, 1H), 3.31–3.22 (m, 1H), 2.59–2.49 (m, 1H), 2.37 (s, 3H), 2.27–2.19 (m, 1H), 1.13 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.4, 169.7, 142.2, 139.8, 137.3, 129.1, 128.8, 127.2, 126.2, 124.7, 64.5, 61.8, 30.3, 24.9, 21.3, 13.8. HRMS (ESI-TOF): Anal. Calcd. For C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>S+Na<sup>+</sup>: 409.1192, Found: 409.1196; IR (neat, cm-1): v 2965, 2922, 2852, 1728, 1560, 1082, 699.



### (E)-4-methyl-N-(2-phenyl-2-azaspiro[4.5]decan-3-ylidene)benzenesulfonamide

(**7b**). Petroleum ether/ ethylacetate = 5:1, white solid, 58.6 mg, 77% yield, mp: 148.3–149.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80–7.78 (m, 2H), 7.48–7.47 (m, 2H), 7.36–7.32 (m, 2H), 7.24–7.17 (m, 3H), 3.65 (s, 2H), 3.16 (s, 2H), 2.38 (s, 3H), 1.55–1.45 (m, 10H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  167.8, 142.1, 140.2, 138.8, 129.1, 128.7, 126.3, 126.2, 122.8, 62.6, 44.2, 38.0, 36.0, 25.4, 22.8, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 383.1788, Found: 383.1772; IR (neat, cm-1):  $\nu$  2919, 2850, 1747, 1558, 1150, 681.



(*E*)-4-methyl-*N*-(1-phenylazetidin-2-ylidene)benzenesulfonamide (7c). Petroleum ether/ ethylacetate = 3:1, light yellow solid, 35.5 mg, 60% yield, mp: 105.9–107.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–7.84 (m, 2H), 7.44–7.42 (m, 2H), 7.35–7.31 (m, 2H), 7.29–7.27 (m, 2H), 7.15–7.11 (m, 1H), 3.98 (t, *J* = 4.1 Hz, 2H), 3.50 (t, *J* = 4.1 Hz, 2H), 2.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.5, 142.8, 139.5, 137.8, 129.3, 129.1, 126.6, 125.1, 117.3, 45.0, 32.3, 21.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 323.0825, Found: 323.0830; IR (neat, cm-1):  $\nu$  2923, 2853, 1734, 1610, 1147, 895, 681.



(*E*)-*N*-(1-phenylazetidin-2-ylidene)thiophene-2-sulfonamide (7d). Petroleum ether/ ethylacetate = 1:3, white solid, 50.2 mg, 86% yield, mp: 128.8–129.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.68–7.67 (m, 1H), 7.55–7.53 (m, 1H), 7.48–7.45 (m, 2H), 7.38–7.34 (m, 2H), 7.18–7.15 (m, 1H), 7.07–7.05 (m, 1H), 4.02 (t, *J* = 4.1 Hz, 2H), 3.53 (t, *J* = 4.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  164.8, 143.7, 137.7, 131.1, 131.0, 129.2, 127.0, 125.4, 117.5, 45.2, 32.2. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub>+H<sup>+</sup>: 293.0413, Found: 293.0417; IR (neat, cm-1): υ 2920. 1735, 1307, 1138, 1015, 891, 681.



(*E*)-3-nitro-*N*-(1-phenylazetidin-2-ylidene)benzenesulfonamide (7e). Petroleum ether/ ethylacetate = 1:3, white solid, 43.8 mg, 66% yield, mp: 160.6–161.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.805–8.796 (m, 1H), 8.40–8.38 (m, 1H), 8.32–8.30 (m, 1H), 7.74–7.70 (m, 1H), 7.44– 7.42 (m, 2H), 7.38–7.34 (m, 2H), 7.19–7.16 (m, 1H), 4.08 (t, *J* = 4.1 Hz, 2H), 3.58 (t, *J* = 4.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  165.0, 148.1, 144.4, 137.5, 132.3, 130.2, 129.2, 126.6, 125.7, 121.9, 117.5, 45.3, 32.6. HRMS (ESI-TOF): Anal. Calcd. For C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S+H<sup>+</sup>: 332.0700, Found: 332.0697; IR (neat, cm-1): v 2919, 1576, 1347, 1013, 895, 762, 677.



(*E*)-4-methyl-*N*-(1-methylpyrrolidin-2-ylidene)benzenesulfonamide (7f). Petroleum ether/ ethylacetate = 1:1, white solid, 46.8 mg, 93% yield, mp: 157.8–159.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82–7.80 (m, 2H), 7.26–7.24 (m, 2H), 3.45 (t, *J* = 7.3 Hz, 2H), 3.03 (t, *J* = 8.0 Hz, 2H), 2.96 (s, 3H), 2.39 (s, 3H), 2.08–2.00 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.8, 141.9, 140.5, 129.1, 126.4, 51.6, 31.9, 30.6, 21.4, 18.9. HRMS (ESI-TOF): Anal. Calcd. For C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 275.0825, Found: 375.0834; IR (neat, cm-1): v 2922, 2852, 1733, 1596, 1278, 668.



(*E*)-*N*-(1-ethylpyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (7g). Petroleum ether/ ethylacetate = 1:1, white solid, 38.5 mg, 73% yield, mp: 106.0–107.0 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82–7.80 (m, 2H), 7.26–7.24 (m, 2H), 3.49–3.43 (m, 4H), 3.03 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.07–2.00 (m, 2H), 1.13 (t, *J* = 7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.3, 141.9, 140.6, 129.1, 126.4, 48.8, 39.6, 31.0, 21.4, 19.0, 11.7. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 289.0981, Found: 289.0989; IR (neat, cm-1): v 2922, 2852, 1729, 1579, 1280, 1142, 666.

(*E*)-4-methyl-*N*-(1-octylpyrrolidin-2-ylidene)benzenesulfonamide (7h). Petroleum ether/ ethylacetate = 3:1, white solid, 53.0 mg, 76% yield, mp: 81.2-82.1 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.81–7.79 (m, 2H), 7.25–7.23 (m, 2H), 3.45–3.38 (m, 4H), 3.04 (t, *J* = 8.0 Hz, 2H), 2.39 (s, 3H), 2.07–1.99 (m, 2H), 1.56–1.50 (m, 2H), 1.34–1.22 (m, 10H), 0.88 (t, *J* = 6.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.6, 141.8, 140.7, 129.0, 126.3, 49.4, 44.8, 31.7, 31.0, 29.1, 29.0, 26.6, 26.5, 22.5, 21.4, 19.1, 14.0. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 373.1920, Found: 373.1921; IR (neat, cm-1): v 2925, 2852, 1732, 1580, 1303, 1143, 672.



(*E*)-*N*-(1-cyclohexylpyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (7i). Petroleum ether/ ethylacetate = 4:1, white solid, 37.4 mg, 59% yield, mp: 188.6–190.5 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.81–7.79 (m, 2H), 7.26–7.24 (m, 2H), 4.20–4.13 (m, 1H), 3.40 (t, *J* = 7.3 Hz, 2H), 3.01 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.02–1.95 (m, 2H), 1.80–1.66 (m, 5H), 1.43–1.30 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.1, 141.8, 140.8, 129.1, 126.4, 52.8, 45.0, 31.3, 29.6, 25.3, 25.1,
21.4, 19.1. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 343.1451, Found: 343.1461; IR (neat, cm-1): v 2921, 2849, 1733, 1556, 1137, 666.



(*E*)-*N*-(1-benzylpyrrolidin-2-ylidene)-4-methylbenzenesulfonamide (7j). Petroleum ether/ ethylacetate = 3:1, white solid, 56.4 mg, 86% yield, mp: 137.7–139.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84–7.82 (m, 2H), 7.31–7.25 (m, 5H), 7.21–7.18 (m, 2H), 4.58 (s, 2H), 3.34 (t, *J* = 7.3 Hz, 2H), 3.10 (t, *J* = 8.0 Hz, 2H), 2.40 (s, 3H), 2.04–1.97 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.8, 142.0, 140.4, 134.9, 129.1, 128.7, 128.3, 127.9, 126.4, 48.8, 48.6, 30.9, 21.4, 18.9. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 351.1138, Found: 351.1147; IR (neat, cm-1):  $\upsilon$  2923, 2854, 1749, 1571, 1140, 667.



(*E*)-*N*-methyl-*N*-phenyl-*N'*-tosylacetimidamide (8a). Petroleum ether/ ethylacetate = 5:1, white solid, 59.2 mg, 98% yield, mp: 78.5–79.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.91–7.89 (m, 2H), 7.46–7.42 (m, 2H), 7.40–7.36 (m, 1H), 7.30–7.28 (m, 2H), 7.16–7.14 (m, 2H), 3.34 (s, 3H), 2.41 (s, 3H), 2.29 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 166.0, 143.1, 142.0, 140.8, 130.0, 129.1, 128.5, 126.7, 126.3, 40.3, 21.4, 19.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 303.1162, Found: 303.1170; IR (neat, cm-1): υ 2921, 2869, 1745, 1537, 1270, 1083, 770, 681.



(*E*)-*N*,*N*-diphenyl-*N'*-tosylacetimidamide (8b). Petroleum ether/ ethylacetate = 4:1, light yellow solid, 71.5 mg, 99% yield, mp: 147.9–148.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.62–7.60 (m, 2H), 7.35–7.21 (m, 10H), 7.15–7.13 (m, 2H), 2.53 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  166.3, 141.8, 140.4, 129.6, 129.4, 128.8, 127.1, 126.3, 126.0, 21.3, 20.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 365.1318, Found: 365.1315; IR (neat, cm-1):  $\upsilon$  2917, 2849, 1743, 1489, 1271, 1088, 684.



(*E*)-*N*-methyl-*N*-phenyl-*N'*-tosylbenzimidamide (8c). Petroleum ether/ ethylacetate = 4:1, white solid, 40.7 mg, 56% yield, mp: 104.7–106.1 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.62–7.60 (m, 2H), 7.19–7.05 (m, 10H), 6.95–6.93 (m, 2H), 3.52 (s, 3H), 2.36 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  166.6, 143.3, 141.7, 140.7, 132.3, 129.4, 129.1, 128.8, 128.7, 127.4, 127.3, 127.3, 126.5, 40.8, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 387.1138, Found: 387.1139; IR (neat, cm-1):  $\nu$  3355, 3260, 2921, 2851, 1741, 1522, 1147, 679.



(*E*)-*N*-(1-(indolin-1-yl)ethylidene)-4-methylbenzenesulfonamide (8d). Petroleum ether/ ethylacetate = 2:1, white solid, 58.1 mg, 93% yield, mp: 177.5–178.6 °C. <sup>1</sup>H NMR (400 MHz,

CDCl<sub>3</sub>)  $\delta$  8.20–8.18 (m, 1H), 7.87–8.86 (m, 2H), 7.28–7.26 (m, 2H), 7.17–7.15 (m, 1H), 7.10–7.01 (m, 2H), 4.03 (t, *J* = 8.2 Hz, 2H), 3.15 (t, *J* = 8.1 Hz, 2H), 2.63 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.2, 142.1, 141.7, 140.6, 132.7, 129.2, 127.4, 126.3, 125.0, 124.6, 119.3, 49.7, 27.1, 21.4, 20.6. HRMS (ESI-TOF): Anal. Calcd. For C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 315.1162, Found: 315.1169; IR (neat, cm-1): v 2918, 2849, 1734, 1132, 754, 660.



(*E*)-*N*-(1-(3,4-dihydroquinolin-1(2*H*)-yl)ethylidene)-4-methylbenzenesulfonamide (8e). Petroleum ether/ ethylacetate = 5:1, white solid, 63.6 mg, 97% yield, mp: 104.5–107.1 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.90–7.88 (m, 2H), 7.29–7.27 (m, 2H), 7.22–7.18 (m, 3H), 7.03–7.02 (m, 1H), 3.87 (t, *J* = 6.9 Hz, 2H), 2.67 (t, *J* = 6.5 Hz, 2H), 2.63 (s, 3H), 2.41 (s, 3H), 1.97–1.90 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  165.0, 142.0, 140.6, 137.5, 129.0, 128.3, 127.0, 126.4, 126.2, 126.1, 124.8, 45.8, 26.4, 23.7, 21.3, 20.1. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 329.1318, Found: 329.1326; IR (neat, cm-1): v 2922, 2851, 1749, 1492, 1082, 753.



(*E*)-*N*-(2-(4-chlorophenoxy)-1-(pyrrolidin-1-yl)ethylidene)-4-methylbenzenesulfo namide (8f). Petroleum ether/ ethylacetate = 3:1, white solid, 53.2 mg, 68% yield, mp: 118.8–120.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82–7.80 (m, 2H), 7.23– 7.21 (m, 4H), 6.89–6.87 (m, 2H), 5.26 (s, 2H), 3.62 (t, *J* = 6.7 Hz, 2H), 3.53 (t, *J* = 7.0 Hz, 2H), 2.38 (s, 3H), 1.98–1.91 (m, 2H), 1.88–1.82 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.0, 155.7, 142.0, 140.8, 129.4, 129.0, 126.8, 126.2, 115.8, 64.2, 49.4, 48.7, 26.0, 23.5, 21.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>19</sub>H<sub>21</sub><sup>35</sup>CIN<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 393.1034, C<sub>19</sub>H<sub>21</sub><sup>37</sup>CIN<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 395.1005, Found: 393.1024, 395.0978; IR (neat, cm-1):  $\nu$  2921, 2851, 1541, 1082, 837, 696.



## (E)-4-methyl-N-(3-phenyl-1-(pyrrolidin-1-yl)propylidene)benzenesulfonamide

(**8g**). Petroleum ether/ ethylacetate = 4:1, white solid, 39.5 mg, 56% yield, mp: 126.6–128.5 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.89–7.87 (m, 2H), 7.31–7.19 (m, 7H), 3.49 (t, J = 6.5 Hz, 2H), 3.30 (t, J = 6.2 Hz, 2H), 3.15–3.11 (m, 2H), 3.08–3.04 (m, 2H), 2.39 (s, 3H), 1.86–1.80 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.6, 141.7, 141.6, 140.1, 129.0, 128.5, 128.5, 126.5, 126.1, 48.6, 47.5, 34.8, 32.8, 25.7, 24.1, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 357.1631, Found: 357.1624; IR (neat, cm-1):  $\nu$  2919, 2850, 1747, 1541, 1252, 697.



(*E*)-*N*-(cyclohexyl(morpholino)methylene)-4-methylbenzenesulfonamide (8h). Petroleum ether/ ethylacetate = 2:1, white solid, 31.5 mg, 45% yield, mp: 133.9–135.0 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.81–7.79 (m, 2H), 7.26–7.24 (m, 2H), 3.72–3.62 (m, 9H), 2.40 (s, 3H), 1.87– 1.70 (m, 6H), 1.61–1.52 (m, 2H), 1.19–1.13 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.0, 141.7, 141.6, 129.0, 126.1, 66.6, 47.6, 43.4, 40.2, 29.6, 29.2, 28.3, 26.0, 25.7, 25.4, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 351.1737, Found: 351.1725; IR (neat, cm-1):  $\upsilon$ 2922, 2850, 1740, 1534, 1138, 870, 667.



(*E*)-4-methyl-*N*-(1-morpholinoethylidene)benzenesulfonamide (8i). Petroleum ether/ ethylacetate = 1:1, white solid, 49.2 mg, 88% yield, mp: 116.7–117.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.81–7.79 (m, 2H), 7.27–7.25 (m, 2H), 3.75–3.73 (m, 2H), 3.72–3.69 (m, 2H), 3.67–3.65 (m, 2H), 3.53–3.50 (m, 2H), 2.52 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  164.5, 142.0, 140.7, 129.1, 126.2, 66.2, 66.2, 46.5, 44.5, 21.4, 17.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S+Na<sup>+</sup>: 305.0930, Found: 309.0940; IR (neat, cm-1): v 2921, 2856, 1730, 1535, 1260, 675.



**Methyl** (*E*)-(1-(tosylimino)ethyl)-*L*-prolinate (8j). Petroleum ether/ ethylacetate = 1:1, colorless sticky liquid, 42.0 mg, 65% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.75–7.73 (m, 2H), 7.24–7.22 (m, 2H), 4.53–4.50 (m, 1H), 3.71–3.66 (m, 1H), 3.59–3.55 (m, 1H), 3.53 (s, 3H), 2.51 (s, 3H), 2.39 (s, 3H), 2.25–2.10 (m, 2H), 2.04–2.00 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.7, 164.0, 141.8, 140.7, 128.9, 126.1, 60.7, 52.0, 48.4, 29.2, 24.3, 21.4, 18.8. HRMS (ESI-TOF): Anal. Calcd. For C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S+H<sup>+</sup>: 325.1217, Found: 325.1203; IR (neat, cm-1): v 2923, 2852, 1741, 1538, 114, 704.



(*E*)-*N*,*N*-dimethyl-*N'*-tosylacetimidamide (8k). Petroleum ether/ ethylacetate = 1:1, white solid, 32.2 mg, 68% yield, mp: 105.6–107.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.83–7.81 (m, 2H), 7.26–7.24 (m, 2H), 3.09 (s, 3H), 3.07 (s, 3H), 2.49 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  165.8, 141.8, 141.1, 129.1, 126.2, 38.8, 38.8, 21.4, 18.0. HRMS (ESI-TOF): Anal. Calcd. For

C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 263.0825, Found: 263.0831; IR (neat, cm-1): v 2921, 2851, 1729, 1572, 1251, 683.



(*E*)-2-chloro-*N*,*N*-diethyl-*N'*-tosylacetimidamide (81). Petroleum ether/ ethylacetate = 3:1, yellow solid, 24.7 mg, 40% yield, mp:  $68.5-69.5 \,^{\circ}$ C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84–7.82 (m, 2H), 7.27–7.24 (m, 2H), 4.71 (s, 2H), 3.51–3.44 (m, 4H), 2.40 (s, 3H), 1.28 (t, *J* = 8.0 Hz, 3H), 1.09 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.8, 142.1, 140.5, 129.0, 126.2, 43.6, 43.5, 34.4, 21.4, 14.1, 11.6. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>19</sub><sup>35</sup>ClN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 325.0748, C<sub>13</sub>H<sub>19</sub><sup>37</sup>ClN<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 327.0718, Found: 325.0758, 327.0714; IR (neat, cm-1): v 2978, 2874, 1733, 1556, 1143, 669.



(*E*)-*N*,*N*-dimethyl-*N'*-tosylformimidamide (9a). Petroleum ether/ ethylacetate = 1:1, white solid, 44.4 mg, 98% yield, mp: 124.3–125.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 (s, 1H), 7.78–7.76 (m, 2H), 7.26–7.24 (m, 2H), 3.12 (s, 3H), 3.00 (s, 3H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.0, 142.3, 139.5, 129.2, 126.4, 41.4, 35.4, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 249.0668, Found: 249.0676; IR (neat, cm-1): v 2922, 2852, 1619, 1278, 1143, 910, 667.

(E)-N-methyl-N-phenyl-N'-tosylformimidamide (9b). Petroleum ether/ ethylacetate =
5:1, white solid, 56.9 mg, 99% yield, mp: 94.7–96.0 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.57 (s, 1H),
7.84–7.82 (m, 2H), 7.45–7.41 (m, 2H), 7.34–7.28 (m, 3H), 7.20–7.19 (m, 2H), 3.44 (s, 3H), 2.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.3, 143.1, 142.8, 138.8, 129.8, 129.3, 127.2, 126.6, 122.0,

35.9, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 289.1005, Found: 289.1016; IR (neat, cm-1): υ 2921, 2851, 1743, 1566, 1143, 763, 672.



(*E*)-*N*,*N*-diethyl-*N'*-tosylformimidamide (9c). Petroleum ether/ ethylacetate = 2:1, white solid, 50.2 mg, 99% yield, mp: 54.5–55.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (s, 1H), 7.77–7.75 (m, 2H), 7.26–7.24 (m, 2H), 3.47 (q, *J* = 7.2 Hz, 2H), 3.38 (q, *J* = 7.2 Hz, 2H), 2.39 (s, 3H), 1.25 (t, *J* = 7.2 Hz, 3H), 1.13 (t, *J* = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.0, 142.1, 139.7, 129.2, 126.2, 46.9, 40.8, 21.3, 14.4, 12.0. HRMS (ESI-TOF): Anal. Calcd. For C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+Na<sup>+</sup>: 277.0981, Found: 277.0976; IR (neat, cm-1): v 2984, 2875, 1748, 1607, 1280, 1142, 670.



(*E*)-*N*,*N*-diisopropyl-*N'*-tosylformimidamide (9d). Petroleum ether/ ethylacetate = 5:1, white solid, 55.0 mg, 98% yield, mp: 103.6–104.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.25 (s, 1H), 7.76–7.74 (m, 2H), 7.26–7.24 (m, 2H), 4.52 (dt, *J* =13.6, 6.8 Hz, 1H), 3.69 (dt, *J* = 13.6, 6.8 Hz, 1H), 2.39 (s, 3H), 1.31 (d, *J* = 6.8 Hz, 6H), 1.21 (d, *J* = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.2, 142.0, 139.8, 129.1, 126.1, 48.4, 47.8, 23.5, 21.3, 19.5. HRMS (ESI-TOF): Anal. Calcd. For C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 283.1475, Found: 283.1478; IR (neat, cm-1):  $\upsilon$  2925, 2854, 1747, 1595, 1146, 669.



(*E*)-4-methyl-*N*-(piperidin-1-ylmethylene)benzenesulfonamide (9e). Petroleum ether/ ethylacetate = 3:1, white solid, 52.7 mg, 99% yield, mp: 150.3–151.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.12 (s, 1H), 7.77–7.75 (m, 2H), 7.26–7.24 (m, 2H), 3.58 (t, *J* = 5.0 Hz, 2H), 3.41 (t, *J* = 5.0 Hz, 2H), 2.39 (s, 3H), 1.70–1.66 (m, 4H), 1.59–1.55 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.2, 142.2, 139.6, 129.2, 126.3, 51.8, 44.5, 26.3, 24.7, 23.8, 21.3. HRMS (ESI-TOF): Anal. Calcd. For C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S+H<sup>+</sup>: 267.1162, Found: 267.1170; IR (neat, cm-1): υ 2924, 2856, 1732, 1603, 1145, 670.

(*E*)-4-methyl-*N*-(morpholinomethylene)benzenesulfonamide (9f). Petroleum ether/ ethylacetate = 1:1, white solid, 52.9 mg, 99% yield, mp: 164.1–165.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.22 (s, 1H), 7.77–7.75 (m, 2H), 7.28–7.26 (m, 2H), 3.75–3.72 (m, 2H), 3.66 (s, 4H), 3.51–3.49 (m, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.6, 142.5, 139.1, 129.3, 126.4, 66.7, 65.8, 50.2, 44.1, 21.4. HRMS (ESI-TOF): Anal. Calcd. For C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S+H<sup>+</sup>: 269.0954, Found: 269.0961; IR (neat, cm-1): v 2922, 2851, 1735, 1605, 853, 668.

## References

- 1. J. Yin and S. L. Buchwald, Org. Lett., 2000, 2, 1101.
- 2. G. Barbe and A. B. Charette, J. Am. Chem. Soc., 2008, 130, 18.
- 3. B. Peng, D. Geerdink, C. Far ès and N. Maulide, Angew. Chem. Int. Ed., 2014, 53, 5462.

## Spectroscopic data for products

















S51























- 10 - 0 - -10 - -20



















190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 fl(ppm)
























S79



































S91





S93
















































S113



















## XRD data of the compound 4a



Figure S2. ORTEP structural drawing of 4a. (CCDC: 1565960)

complex	4a
Empirical formula	$C_{17}H_{18}N_2O_2S$
Formula weight(g mol <sup>-1</sup> )	314.39
Temperature	120 (2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
space group	P2 (1) /n
	a = 12.3640 (7) Å
	b = 7.4331 (4) Å
Unit call dimensions	c = 16.5987 (9)  Å
Unit cell dimensions	$\alpha = 90$ °
	$\beta = 105.575$ (2) °
	$\gamma = 90$ °
Volume (Å <sup>3</sup> )	1469.45 (14)
Z	4
ρ(g cm <sup>-3</sup> )	1.421

 $Table \ S3. \ Crystallography \ data \ for \ 4a.$ 

F(000)	664
Crystal size(mm <sup>3</sup> )	0.20 x 0.15 x 0.10
Theta range for data collection	1.84 °to 25.50 °
	-14<=h<=14
Limiting indices	-9<=k<=9
	-20<=l<=20
Reflections collected / unique	19816 / 2716
Data / restraints / parameters	2716 / 0 / 200
GOF	1.188
$R1, wR2[I > 2\sigma(I)]$	R1 = 0.0328
	wR2 = 0.0940
<i>R1,wR2</i> (all data)	R1 = 0.0395
	wR2 = 0.1085
Largest diff. peak and hole(e $Å^3$ )	0.368 and -0.516

## Table S4. Bond lengths [Å] and angles [ ] for 4a.

S(1)-O(2) 1.4397(13)	S(1)-O(1) 1.4400(13)	S(1)-N(1) 1.6226(15)	S(1)-C(15) 1.7707(18)
N(1)-C(1) 1.308(2)	N(2)-C(1) 1.353(2)	N(2)-C(5) 1.424(2)	N(2)-C(4) 1.481(2)
C(1)-C(2) 1.503(2)	C(2)-C(3) 1.526(2)	C(3)-C(4) 1.522(3)	C(5)-C(6) 1.395(2)
C(5)-C(10) 1.400(2)	C(6)-C(7) 1.386(3)	C(7)-C(8) 1.387(3)	C(8)-C(9) 1.389(3)
C(9)-C(10) 1.385(3)	C(11)-C(12) 1.507(3)	C(12)-C(17) 1.390(3)	C(12)-C(13) 1.400(3)
C(13)-C(14) 1.380(3)	C(14)-C(15) 1.391(2)	C(15)-C(16) 1.389(2)	C(16)-C(17) 1.392(3)
O(2)-S(1)-O(1) 117.05(8)	O(2)-S(1)-N(1) 113.00(8)	O(1)-S(1)-N(1) 105.37(7)	O(2)-S(1)-C(15) 107.35(8)
O(1)-S(1)-C(15) 107.00(8)	N(1)-S(1)-C(15) 106.47(8)	C(1)-N(1)-S(1) 120.16(12)	C(1)-N(2)-C(5) 127.01(14)
C(1)-N(2)-C(4) 112.40(14)	C(5)-N(2)-C(4) 119.87(14)	N(1)-C(1)-N(2) 121.58(16)	N(1)-C(1)-C(2) 129.36(16)
N(2)-C(1)-C(2) 109.03(15)	C(1)-C(2)-C(3) 104.94(15)	C(4)-C(3)-C(2) 104.48(14)	N(2)-C(4)-C(3) 103.79(14)
C(6)-C(5)-C(10) 119.17(16)	C(6)-C(5)-N(2) 118.42(16)	C(10)-C(5)-N(2) 122.40(15)	C(7)-C(6)-C(5) 120.71(17)
C(6)-C(7)-C(8) 120.02(17)	C(7)-C(8)-C(9) 119.48(17)	C(10)-C(9)-C(8) 120.98(17)	C(9)-C(10)-C(5) 119.61(16)
C(17)-C(12)-C(13) 118.49(17)	C(17)-C(12)-C(11) 120.50(16)	C(13)-C(12)-C(11) 121.01(17)	C(14)-C(13)-C(12) 121.19(17)
C(13)-C(14)-C(15) 119.33(16)	C(16)-C(15)-C(14) 120.72(17)	C(16)-C(15)-S(1) 119.06(14)	C(14)-C(15)-S(1) 120.07(13)
C(15)-C(16)-C(17) 119.16(17)	C(12)-C(17)-C(16) 121.07(16)		

## XRD data of the compound 8d



Figure S3. ORTEP structural drawing of 8d. (CCDC: 1565961)

complex	8d
Empirical formula	$C_{17}H_{18}N_2O_2S$
Formula weight(g mol <sup>-1</sup> )	314.39
Temperature	120 (2) K
Wavelength	0.71073 Å
Crystal system	Triclinic
space group	P-1
	a = 7.4252 (7) Å
	b = 9.8673 (10) Å
	c = 11.2350 (11) Å
Unit cell dimensions	$\alpha = 77.187(3)^{\circ}$
	$\beta = 79.103(3)^{\circ}$
	$\gamma = 69.194(3)^{\circ}$
Volume (Å <sup>3</sup> )	744.80 (13)
Z	2
ρ(g cm <sup>-3</sup> )	1.402
F(000)	332
Crystal size(mm <sup>3</sup> )	0.22 x 0.20 x 0.18

**Table S5.** Crystallography data for 8d.

Theta range for data collection	1.87 °to 27.55 °
	-9<=h<=9
Limiting indices	-12<=k<=12
	-14<=l<=14
Reflections collected / unique	15180 / 3404
Data / restraints / parameters	3404 / 0 /201
GOF	1.096
$R1, wR2[I > 2\sigma(I)]$	R1 = 0.0418
	wR2 = 0.1133
<i>R1,wR2</i> (all data)	R1 = 0.0558
	wR2 = 0.1321
Largest diff. peak and hole(e Å <sup>3</sup> )	0.428 and -0.489

 Table S6. Bond lengths [Å] and angles [ ] for 8d.

S(1)-O(2) 1.4378(14)	S(1)-O(1) 1.4426(14)	S(1)-N(2) 1.6123(16)	S(1)-C(5) 1.7663(19)
N(1)-C(8) 1.346(2)	N(1)-C(17) 1.422(2)	N(1)-C(10) 1.487(2)	N(2)-C(8) 1.316(2)
C(1)-C(2) 1.508(3)	C(2)-C(7) 1.388(3)	C(2)-C(3) 1.398(3)	C(3)-C(4) 1.386(3)
C(4)-C(5) 1.393(2)	C(5)-C(6) 1.387(2)	C(6)-C(7) 1.387(3)	C(8)-C(9) 1.500(3)
C(10)-C(11) 1.526(3)	C(11)-C(12) 1.500(3)	C(12)-C(13) 1.377(3)	C(12)-C(17) 1.398(3)
C(13)-C(14) 1.392(3)	C(14)-C(15) 1.386(3)	C(15)-C(16) 1.396(3)	C(16)-C(17) 1.392(3)
O(2)-S(1)-O(1) 116.39(8)	O(2)-S(1)-N(2) 105.08(8)	O(1)-S(1)-N(2) 114.52(8)	O(2)-S(1)-C(5) 107.37(8)
O(1)-S(1)-C(5) 107.82(8)	N(2)-S(1)-C(5) 104.89(9)	C(8)-N(1)-C(17) 128.34(15)	C(8)-N(1)-C(10) 122.03(15)
C(17)-N(1)-C(10) 109.63(14)	C(8)-N(2)-S(1) 124.18(14)	C(7)-C(2)-C(3) 118.37(17)	C(7)-C(2)-C(1) 121.05(17)
C(3)-C(2)-C(1) 120.57(18)	C(4)-C(3)-C(2) 121.43(17)	C(3)-C(4)-C(5) 118.95(17)	C(6)-C(5)-C(4) 120.51(17)
C(6)-C(5)-S(1) 120.12(14)	C(4)-C(5)-S(1) 119.31(13)	C(7)-C(6)-C(5) 119.65(18)	C(6)-C(7)-C(2) 121.05(17)
N(2)-C(8)-N(1) 117.25(16)	N(2)-C(8)-C(9) 126.62(17)	N(1)-C(8)-C(9) 116.14(17)	N(1)-C(10)-C(11) 105.90(15)
C(12)-C(11)-C(10) 104.22(15)	C(13)-C(12)-C(17) 120.31(17)	C(13)-C(12)-C(11) 128.89(17)	C(17)-C(12)-C(11) 110.80(16)
C(12)-C(13)-C(14) 119.42(18)	C(15)-C(14)-C(13) 119.99(18)	C(14)-C(15)-C(16) 121.54(18)	C(17)-C(16)-C(15) 117.60(17)
C(16)-C(17)-C(12) 121.13(17)	C(16)-C(17)-N(1) 129.42(16)	C(12)-C(17)-N(1) 109.44(16)	